Frequency Allocation for Hearing Loss
Trial Summary
The trial protocol does not specify whether you need to stop taking your current medications.
Research on cochlear 'dead regions' suggests that enhancing frequency discrimination near these areas can improve hearing, which may support the use of customized frequency mapping in the treatment. Additionally, studies on high frequency audiometry indicate its potential for early detection of hearing issues, suggesting that frequency allocation adjustments could be beneficial.
12345The Experimental Frequency Allocation Table treatment is unique because it customizes frequency mapping based on individual anatomy, potentially enhancing frequency discrimination by targeting specific 'dead regions' in the cochlea. This approach differs from standard treatments by focusing on personalized frequency allocation to improve hearing outcomes.
25678Eligibility Criteria
This trial is for people with mixed conductive and sensorineural hearing loss, deafness, or general hearing loss who already use a cochlear implant (CI). Specific eligibility criteria are not provided, but typically participants must meet certain health standards and agree to follow the study procedures.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Experimental FAT Adaptation
Participants are fitted with an experimental frequency allocation table (FAT) and undergo a 1-month adaptation period
Standard FAT Re-adaptation
Participants undergo a 1-month re-adaptation to the standard frequency allocation table (FAT)
Follow-up
Participants are monitored for safety and effectiveness after treatment